Phase 1 study of the selective BTK inhibitor zanubrutinib in B-cell malignancies and safety and efficacy evaluation in CLL

Zanubrutinib is a potent and highly selective inhibitor of Bruton tyrosine kinase (BTK). In this first-in-human, open-label, multicenter, phase 1 study, patients in part 1 (3 + 3 dose escalation) had relapsed/refractory B-cell malignancies and received zanubrutinib 40, 80, 160, or 320 mg once daily...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Blood
Hlavní autoři: Tam, Constantine S., Trotman, Judith, Opat, Stephen, Burger, Jan A., Cull, Gavin, Gottlieb, David, Harrup, Rosemary, Johnston, Patrick B., Marlton, Paula, Munoz, Javier, Seymour, John F., Simpson, David, Tedeschi, Alessandra, Elstrom, Rebecca, Yu, Yiling, Tang, Zhiyu, Han, Lynn, Huang, Jane, Novotny, William, Wang, Lai, Roberts, Andrew W.
Médium: Artigo
Jazyk:Inglês
Vydáno: American Society of Hematology 2019
Témata:
Clinical Trials and Observations
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6742923/
https://ncbi.nlm.nih.gov/pubmed/31340982
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood.2019001160
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky